- AbbVie Deserves A Higher Multiple
May 11, 2026 · seekingalpha.com
AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.
- AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
May 11, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments.
AbbVie is a large biopharmaceutical company with a significant presence in immunology, where treatments for Crohn's disease and ulcerative colitis are key areas of focus. The new data on SKYRIZI and RINVOQ add detail on how these therapies are performing in practice, beyond initial trial results. For investors, this type of clinical update helps frame how AbbVie is supporting its existing immunology franchise while working within a competitive treatment market.
The fresh evidence around sustained patient outcomes and satisfaction may influence how physicians and patients view SKYRIZI and RINVOQ among available options. For readers tracking NYSE:ABBV, the news provides additional context on how AbbVie is positioning its gastroenterology portfolio to address ongoing treatment needs in inflammatory bowel disease.
Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.NYSE:ABBV Earnings & Revenue Growth as at May 2026
3 things going right for AbbVie that this headline doesn't cover.
For AbbVie, the new long term data on SKYRIZI and RINVOQ goes beyond headline efficacy and speaks directly to how these drugs are used in real clinical practice. Lower switch rates versus several other biologics in Crohn's disease and reduced use of corticosteroids and over the counter therapies by Week 52 suggest that once patients are on these treatments, many stay on them and may rely less on supportive medications. That supports the idea of durable prescriptions in inflammatory bowel disease, an area where AbbVie competes with companies such as Johnson & Johnson, Pfizer and Takeda. The reported improvements in quality of life, work productivity and patient satisfaction also matter for market access, because they feed into health economic arguments that payers assess when deciding reimbursement and positioning on formularies. For investors, this combination of real world persistence, quality of life benefits and ongoing formulary listings, such as the recent Canadian updates for SKYRIZI, points to AbbVie working to defend and extend its immunology franchise at a time when the company is looking to newer therapies to support the broader business.
Story Continues
How This Fits Into The AbbVie Narrative
The DDW data supports the narrative that expansion in immunology, particularly through SKYRIZI and RINVOQ, can help offset pressure on older products by reinforcing their role across high need indications like Crohn's disease and ulcerative colitis. At the same time, the focus on a concentrated set of therapies in immunology and related areas underlines a key narrative concern around product concentration risk if competitors or pricing rules eventually limit uptake. The depth of real world evidence around reduced hospitalizations and emergency visits for patients switched to RINVOQ, and detailed quality of life outcomes for SKYRIZI, is not fully captured in the higher level narrative and may influence how payers and clinicians view these drugs over time.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for AbbVie to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Analysts have flagged that AbbVie carries a high level of debt and negative shareholders' equity, which can limit flexibility if market conditions or product performance turn less favorable. ⚠️ There is concentrated exposure to immunology, so any future safety concerns, competitive therapies or pricing reforms affecting key products like SKYRIZI and RINVOQ could weigh on earnings stability. 🎁 Earnings are forecast by analysts to grow 25.14% per year, supported in part by newer therapies and indication expansions in areas such as gastroenterology and dermatology. 🎁 The stock is assessed as trading at 51.8% below one estimate of fair value and analysts are in good agreement that the share price could rise by 25.1%, which many investors view as a supportive reward profile if the pipeline and current portfolio deliver as expected.
What To Watch Going Forward
Following this data release, it is worth watching how quickly the new SKYRIZI and RINVOQ evidence is reflected in treatment guidelines, prescribing behavior and payer decisions in key markets. Investors may also want to track whether real world outcomes such as lower switch rates and reduced hospital use hold up in broader datasets over time, and how that compares with treatments from peers like Johnson & Johnson and Pfizer. In parallel, AbbVie's upcoming regulatory milestones, such as the subcutaneous induction filing for SKYRIZI in Crohn's disease and further indications for RINVOQ, will help clarify how far the immunology franchise can extend its reach within inflammatory and autoimmune diseases.
To ensure you're always in the loop on how the latest news impacts the investment narrative for AbbVie, head to the community page for AbbVie to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABBV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
May 11, 2026 · fool.com
AbbVie's Skyrizi is one of its most important growth drivers. This drug could face competition from a newer medicine under development that appears more effective.
- AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing
May 11, 2026 · seekingalpha.com
AbbVie (ABBV) delivered strong Q1 2026 results, with $15B revenue (+12.4% YoY) and Skyrizi sales up 30.9%, prompting raised EPS guidance. Despite analyst concerns over new oral competitors like Icotyde, Skyrizi maintains a clear efficacy advantage and expanding indications, supporting robust growth. ABBV is trading at 14.2x 2026 EPS with a 0.84x PEG, offering compelling value amid 17% projected earnings growth and a $250/share price target.
- What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
May 10, 2026
Key Points
Chicago-based Cura Wealth Advisors sold 386,000 shares of ARI; the estimated trade size was $4.02 million based on quarterly average prices. Meanwhile, the quarter-end ARI position value declined by $3.35 million, reflecting both trading activity and valuation shifts. The transaction represented 1.8% of 13F AUM for the quarter.10 stocks we like better than Apollo Commercial Real Estate Finance ›
Chicago-based Cura Wealth Advisors disclosed in a May 8, 2026, SEC filing that it sold 386,000 shares of Apollo Commercial Real Estate Finance(NYSE:ARI), an estimated $4.02 million trade based on quarterly average pricing.
What happened
According to a recent SEC filing dated May 8, 2026, Cura Wealth Advisors reduced its holdings in Apollo Commercial Real Estate Finance by 386,000 shares. The estimated value of the trade was approximately $4.02 million, based on the average closing price during the first quarter of 2026. The ARI stake ended the quarter at 437,233 shares, totaling $4.62 million in value.
What else to know
The fund trimmed its ARI position, which now accounts for 2.07% of 13F reportable assets under management.Top five holdings after the filing:
NYSE:ABBV: $63.72 million (28.5% of AUM)NYSE:ABT: $23.58 million (10.6% of AUM)NYSE:FSK: $23.06 million (10.3% of AUM)NASDAQ:MFIC: $6.90 million (3.1% of AUM)NYSEMKT:VT: $5.57 million (2.5% of AUM)As of May 7, 2026, ARI shares were priced at $10.91, up 16% over the past year, compared to a roughly 30% gain from the S&P 500.
Company Overview MetricValuePrice (as of market close 2026-05-07)$10.91Market capitalization$1.45 billionRevenue (TTM)$263.3 millionNet income (TTM)$126.96 million
Company Snapshot
Apollo Commercial Real Estate Finance originates, acquires, and manages commercial first mortgage loans, subordinate financings, and other commercial real estate-related debt investments in the United States.It operates as a mortgage real estate investment trust (REIT), generating income primarily through interest on commercial real estate loans and related investments.It serves institutional investors and commercial property owners seeking real estate financing solutions.
Apollo Commercial Real Estate Finance, Inc. is a mortgage REIT focused on providing commercial real estate debt financing solutions across the United States. Its business model centers on originating and managing a diversified portfolio of commercial real estate loans to generate income for shareholders.
What this transaction means for investors
This sale ultimately looks like a cautious repositioning around commercial real estate exposure rather than a complete loss of confidence in Apollo Commercial Real Estate Finance. Cura Wealth Advisors kept a meaningful stake after the trim, but reducing the position from 1.4% of assets to less than 0.3% suggests the firm may be dialing back risk in a sector that continues to face pressure from higher rates and refinancing uncertainty.
As for fundamentals, Apollo Commercial Real Estate Finance’s latest earnings were relatively stable. The company reported first-quarter net income of $0.16 per diluted share and distributable earnings of $0.22 per share. Plus, the company disclosed no realized investment losses during the quarter, which matters given ongoing investor concerns around commercial property values and office exposure.
Still, the broader backdrop remains difficult for mortgage REITs. Even with shares up about 16% over the last year, ARI has materially lagged the S&P 500, and investors remain wary of how long elevated financing costs could pressure borrowers.
Should you buy stock in Apollo Commercial Real Estate Finance right now?
Before you buy stock in Apollo Commercial Real Estate Finance, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apollo Commercial Real Estate Finance wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 10, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
May 10, 2026
Chicago-based Cura Wealth Advisors disclosed in a May 8, 2026, SEC filing that it sold 386,000 shares of Apollo Commercial Real Estate Finance(NYSE:ARI), an estimated $4.02 million trade based on quarterly average pricing.
What happened
According to a recent SEC filing dated May 8, 2026, Cura Wealth Advisors reduced its holdings in Apollo Commercial Real Estate Finance by 386,000 shares. The estimated value of the trade was approximately $4.02 million, based on the average closing price during the first quarter of 2026. The ARI stake ended the quarter at 437,233 shares, totaling $4.62 million in value.
What else to know
The fund trimmed its ARI position, which now accounts for 2.07% of 13F reportable assets under management. Top five holdings after the filing:
NYSE:ABBV: $63.72 million (28.5% of AUM) NYSE:ABT: $23.58 million (10.6% of AUM) NYSE:FSK: $23.06 million (10.3% of AUM) NASDAQ:MFIC: $6.90 million (3.1% of AUM) NYSEMKT:VT: $5.57 million (2.5% of AUM) As of May 7, 2026, ARI shares were priced at $10.91, up 16% over the past year, compared to a roughly 30% gain from the S&P 500.
Company Overview
Metric Value Price (as of market close 2026-05-07) $10.91 Market capitalization $1.45 billion Revenue (TTM) $263.3 million Net income (TTM) $126.96 million
Company Snapshot
Apollo Commercial Real Estate Finance originates, acquires, and manages commercial first mortgage loans, subordinate financings, and other commercial real estate-related debt investments in the United States. It operates as a mortgage real estate investment trust (REIT), generating income primarily through interest on commercial real estate loans and related investments. It serves institutional investors and commercial property owners seeking real estate financing solutions.
Apollo Commercial Real Estate Finance, Inc. is a mortgage REIT focused on providing commercial real estate debt financing solutions across the United States. Its business model centers on originating and managing a diversified portfolio of commercial real estate loans to generate income for shareholders.
What this transaction means for investors
This sale ultimately looks like a cautious repositioning around commercial real estate exposure rather than a complete loss of confidence in Apollo Commercial Real Estate Finance. Cura Wealth Advisors kept a meaningful stake after the trim, but reducing the position from 1.4% of assets to less than 0.3% suggests the firm may be dialing back risk in a sector that continues to face pressure from higher rates and refinancing uncertainty.
As for fundamentals, Apollo Commercial Real Estate Finance’s latest earnings were relatively stable. The company reported first-quarter net income of $0.16 per diluted share and distributable earnings of $0.22 per share. Plus, the company disclosed no realized investment losses during the quarter, which matters given ongoing investor concerns around commercial property values and office exposure.
Still, the broader backdrop remains difficult for mortgage REITs. Even with shares up about 16% over the last year, ARI has materially lagged the S&P 500, and investors remain wary of how long elevated financing costs could pressure borrowers.
Story Continues
Should you buy stock in Apollo Commercial Real Estate Finance right now?
Before you buy stock in Apollo Commercial Real Estate Finance, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apollo Commercial Real Estate Finance wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 10, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
What This Fund's $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk was originally published by The Motley Fool
View Comments
- What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
May 10, 2026
Key Points
Chicago-based Cura Wealth Advisors sold 155,210 shares of BXMT in the first quarter; the estimated trade size was $2.99 million (based on quarterly average prices). Meanwhile, the quarter-end position value declined by $2.97 million, reflecting share sale and price change. The move represents a 1.34% change in 13F reportable assets under management. Post-sale, Cura held 32,300 BXMT shares valued at $618,545.10 stocks we like better than Blackstone Mortgage Trust ›
On May 8, 2026, Chicago-based Cura Wealth Advisors disclosed in a Securities and Exchange Commission filing that it sold 155,210 shares of Blackstone Mortgage Trust(NYSE:BXMT), with the estimated transaction value at $2.99 million based on quarterly average pricing.
What happened
According to a filing with the Securities and Exchange Commission dated May 8, 2026, Cura Wealth Advisors reduced its holdings in Blackstone Mortgage Trust by 155,210 shares. The estimated value of shares sold was $2.99 million, calculated using the average closing price for the quarter. The value of the position at quarter-end fell by $2.97 million, reflecting both the trade and market movement.
What else to know
This was a sale, leaving Blackstone Mortgage Trust at 0.28% of 13F reportable assets under management as of March 31, 2026.Top holdings after the filing:
NYSE:ABBV: $63.72 million (28.5% of AUM)NYSE:ABT: $23.58 million (10.6% of AUM)NYSE:FSK: $23.06 million (10.3% of AUM)NASDAQ:MFIC: $6.90 million (3.1% of AUM)NYSEMKT:VT: $5.57 million (2.5% of AUM)As of May 7, 2026, BXMT shares were priced at $19.15, roughly flat over the past year and underperforming the S&P 500, which is instead up about 30%.The position was previously 1.4% of the fund's assets as of the prior quarter.
Company overview MetricValueRevenue (TTM)$585.1 millionNet income (TTM)$103.63 millionDividend yield9.82%Price (as of market close May 7, 2026)$19.15
Company snapshot
Blackstone Mortgage Trust originates senior loans secured by commercial real estate properties across North America, Europe, and Australia, generating revenue primarily from interest income.It operates as a mortgage real estate investment trust (REIT), earning income by deploying capital into commercial mortgage loans and distributing a significant portion of taxable income as dividends.It serves institutional borrowers, property owners, and developers seeking large-scale commercial real estate financing solutions.
Blackstone Mortgage Trust is a leading mortgage REIT focused on originating and managing senior commercial real estate loans globally.
What this transaction means for investors
Blackstone Mortgage Trust’s latest earnings report showed a mixed picture that might explain why a wealth advisory like Cura would choose to trim its stake. BXMT posted a first-quarter net loss of $6.3 million, or $0.04 per share, though distributable EPS prior to realized gains and losses came in at $0.49 per share, slightly above the company’s $0.47 dividend. Management emphasized that 98% of the loan portfolio remains performing, with more than half tied to residential and industrial properties rather than office buildings. The firm also maintained roughly $1 billion in liquidity and no corporate debt maturities until 2027.
But even though Blackstone Mortgage Trust has stabilized considerably from the worst of the office-property fears, the stock has still badly lagged the broader market, and some investors may simply be losing patience waiting for sentiment to recover. The nearly 9.4% annualized dividend yield is attractive, but mortgage REITs remain highly sensitive to interest rates, property values, and refinancing conditions, all of which long-term investors should keep in mind.
Should you buy stock in Blackstone Mortgage Trust right now?
Before you buy stock in Blackstone Mortgage Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Blackstone Mortgage Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 10, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
May 10, 2026
On May 8, 2026, Chicago-based Cura Wealth Advisors disclosed in a Securities and Exchange Commission filing that it sold 155,210 shares of Blackstone Mortgage Trust(NYSE:BXMT), with the estimated transaction value at $2.99 million based on quarterly average pricing.
What happened
According to a filing with the Securities and Exchange Commission dated May 8, 2026, Cura Wealth Advisors reduced its holdings in Blackstone Mortgage Trust by 155,210 shares. The estimated value of shares sold was $2.99 million, calculated using the average closing price for the quarter. The value of the position at quarter-end fell by $2.97 million, reflecting both the trade and market movement.
What else to know
This was a sale, leaving Blackstone Mortgage Trust at 0.28% of 13F reportable assets under management as of March 31, 2026. Top holdings after the filing:
NYSE:ABBV: $63.72 million (28.5% of AUM) NYSE:ABT: $23.58 million (10.6% of AUM) NYSE:FSK: $23.06 million (10.3% of AUM) NASDAQ:MFIC: $6.90 million (3.1% of AUM) NYSEMKT:VT: $5.57 million (2.5% of AUM) As of May 7, 2026, BXMT shares were priced at $19.15, roughly flat over the past year and underperforming the S&P 500, which is instead up about 30%. The position was previously 1.4% of the fund's assets as of the prior quarter.
Company overview
Metric Value Revenue (TTM) $585.1 million Net income (TTM) $103.63 million Dividend yield 9.82% Price (as of market close May 7, 2026) $19.15
Company snapshot
Blackstone Mortgage Trust originates senior loans secured by commercial real estate properties across North America, Europe, and Australia, generating revenue primarily from interest income. It operates as a mortgage real estate investment trust (REIT), earning income by deploying capital into commercial mortgage loans and distributing a significant portion of taxable income as dividends. It serves institutional borrowers, property owners, and developers seeking large-scale commercial real estate financing solutions.
Blackstone Mortgage Trust is a leading mortgage REIT focused on originating and managing senior commercial real estate loans globally.
What this transaction means for investors
Blackstone Mortgage Trust’s latest earnings report showed a mixed picture that might explain why a wealth advisory like Cura would choose to trim its stake. BXMT posted a first-quarter net loss of $6.3 million, or $0.04 per share, though distributable EPS prior to realized gains and losses came in at $0.49 per share, slightly above the company’s $0.47 dividend. Management emphasized that 98% of the loan portfolio remains performing, with more than half tied to residential and industrial properties rather than office buildings. The firm also maintained roughly $1 billion in liquidity and no corporate debt maturities until 2027.
But even though Blackstone Mortgage Trust has stabilized considerably from the worst of the office-property fears, the stock has still badly lagged the broader market, and some investors may simply be losing patience waiting for sentiment to recover. The nearly 9.4% annualized dividend yield is attractive, but mortgage REITs remain highly sensitive to interest rates, property values, and refinancing conditions, all of which long-term investors should keep in mind.
Story Continues
Should you buy stock in Blackstone Mortgage Trust right now?
Before you buy stock in Blackstone Mortgage Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Blackstone Mortgage Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 10, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
What to Know About This Fund's $3 Million Blackstone Mortgage Trust Sale Amid Office Stress was originally published by The Motley Fool
View Comments
- AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
May 9, 2026
AbbVie logo
Key Points
Interested in AbbVie Inc.? Here are five stocks we like better. AbbVie reported record 2025 results, with total net revenues of $61.2 billion and adjusted EPS of $10.54, both ahead of expectations. Management said sales grew 8.6% even as Humira continued to face erosion. The company emphasized long-term pipeline and business-development momentum, saying it has nearly 90 clinical programs in development and invested more than $5 billion in external innovation last year. Priority areas include immunology, neuroscience, oncology and obesity. Shareholders approved directors and executive pay but rejected two governance proposals, including a plan to eliminate supermajority voting and a call for an independent board chair. AbbVie also highlighted its U.S. government agreement, which includes Medicaid pricing concessions and a commitment to $100 billion in U.S. R&D and capital investments over the next decade.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.
Rob Michael, AbbVie’s chairman and chief executive officer, said the company delivered total net revenues of $61.2 billion, exceeding its initial expectations by more than $2 billion. Adjusted earnings per share were $10.54, above the company’s initial guidance midpoint excluding the impact of in-process research and development expense.
→ Light Speed Returns: Corning Cashes In on NVIDIA Growth
MarketBeat Week in Review – 04/27 - 05/01
Michael said AbbVie’s sales growth of 8.6% drove an all-time high for revenue, surpassing the company’s previous peak by more than $3 billion despite nearly $16 billion of U.S. Humira erosion since loss of exclusivity.
“This has also fueled a substantial increase in our adjusted R&D investment, fully funding approximately 90 clinical programs currently in development,” Michael said.
Shareholders Elect Directors, Reject Governance Proposals
→ Years in the Making, AMD’s Upside Movement Has Just Begun
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie said proxies representing more than 87% of shares entitled to vote were received, establishing a quorum for the meeting. The company presented five business items: the election of Class II directors, ratification of Ernst & Young as auditor, an advisory vote on executive compensation, a management proposal to eliminate supermajority voting and a shareholder proposal seeking an independent board chair.
Story Continues
Perry Siatis, executive vice president, general counsel and secretary, said preliminary results showed that the director nominees were elected, Ernst & Young’s appointment was ratified and the advisory vote on executive compensation passed.
→ The Hormuz Defense Hedge: Cashing In on Chaos
The management proposal to eliminate supermajority voting did not receive the required vote to approve the amendment. A shareholder proposal calling for an independent board chair was also not approved. AbbVie said final detailed voting results will be available in an upcoming Form 8-K filing.
During the meeting, Lydia Kuykendall, representing Mercy Investment Services and co-filers, argued in favor of requiring an independent board chair. She said pharmaceutical companies face significant legal and regulatory risks and that separating the CEO and chair roles would “eliminate structural conflicts of interest.” Siatis said AbbVie’s board opposed the proposal for the reasons stated in the company’s proxy statement.
Business Development Focuses on Longer-Term Growth
In response to a shareholder question, Michael said AbbVie’s business development efforts have focused on earlier-stage assets that could drive growth in the next decade and beyond, given what he described as a clear growth path into the 2030s from the company’s on-market portfolio and emerging pipeline.
Michael said AbbVie invested more than $5 billion in business development last year. He highlighted several assets and technologies, including an in vivo CAR T platform in immunology from Capstan Therapeutics, bretisilocin for depression, ISB-2001 for multiple myeloma, ABBV-295 for obesity and a next-generation siRNA platform from Arrowhead Pharmaceuticals.
He said AbbVie has “ample financial capacity” to acquire additional external innovation, with a focus on immunology, neuroscience, oncology and obesity.
Company Details U.S. Government Agreement
Siatis also addressed AbbVie’s voluntary agreement with the U.S. government, saying it is intended to advance access and affordability while preserving investment in pharmaceutical innovation.
He said key elements of the three-year agreement include offering low prices for Medicaid, expanding direct-to-patient cash-pay options for Alphagan, Combigan, Humira and Synthroid, and committing $100 billion in U.S. research and development and capital investments over the next decade.
Siatis said AbbVie has already announced more than $2.2 billion in manufacturing investments, including a plant in Durham, North Carolina; plans for three new manufacturing facilities in North Chicago, Illinois; an intention to acquire a manufacturing facility in Tempe, Arizona; and an expansion in Worcester, Massachusetts.
He said the agreement resulted in protection from pharmaceutical tariffs and future pricing mandates, including Most Favored Nation demonstration projects in U.S. government channels, while noting that specific terms are confidential.
Dividend and Pipeline Updates
Scott Reents, executive vice president and chief financial officer, said AbbVie continues to generate substantial free cash flow to support its capital allocation priorities, including internal R&D, business development, a growing dividend and maintenance of an investment-grade credit rating.
Reents said AbbVie increased its quarterly dividend by 5.5% in 2026 to $1.73 per share beginning with the February payable dividend. Since AbbVie’s inception, he said, the quarterly dividend has increased by more than 330%. He added that while the company expects strong dividend growth going forward, it does not expect the dividend to grow at the same rate as earnings.
Michael also outlined recent pipeline progress, including approvals for Rinvoq in giant cell arteritis, Emrelis in non-squamous non-small cell lung cancer and Epkinly in second-line follicular lymphoma. He cited U.S. regulatory submissions for Rinvoq in alopecia areata and subcutaneous induction for Skyrizi in Crohn’s disease.
Other pipeline highlights included interim data from a Crohn’s platform study combining Skyrizi with AbbVie’s alpha-4 beta-7 program, early-stage obesity data for ABBV-295 and a planned regulatory submission for etentamig by the end of the year. Michael also noted the addition of a PD-1/VEGF bispecific antibody from RemeGen.
Michael closed the meeting by thanking shareholders for their confidence in AbbVie and support for the company’s mission.
About AbbVie (NYSE:ABBV)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article "AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting" was originally published by MarketBeat.
View MarketBeat's top stocks for May 2026.
View Comments
- Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Pullback?
May 9, 2026
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in. The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years. Recent coverage has focused on AbbVie's position as a large US pharmaceuticals and biotech company and on how investors are reassessing established drug makers against other healthcare and AI themed opportunities. That context has put more attention on how fairly valued long-running large caps like AbbVie are compared with other parts of the market. On Simply Wall St's framework, AbbVie currently scores 3 out of 6 on valuation checks. This means some measures point to value while others are more cautious. The rest of this article breaks down those methods before finishing with a broader way to think about what AbbVie's valuation indicates.
Find out why AbbVie's 12.8% return over the last year is lagging behind its peers.
Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the business is expected to generate in the future and then discounting those cash flows back to today.
For AbbVie, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $18.0b. Analyst and extrapolated estimates suggest free cash flow of $26.7b in 2026, rising to a projected $34.3b by 2030, with later years extended by Simply Wall St using modest growth assumptions.
When all these projected cash flows are discounted back to today and adjusted for shareholders, the resulting intrinsic value is estimated at about $418.78 per share. Compared with a recent share price around $202, the DCF output implies AbbVie trades at roughly a 51.6% discount to this estimate. On this model alone, the stock appears to be trading below this assessed value.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 51.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.ABBV Discounted Cash Flow as at May 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for AbbVie.
Approach 2: AbbVie Price vs Earnings
For a profitable company like AbbVie, the P/E ratio is a straightforward way to relate what you pay for the stock to the earnings it currently generates. It gives you a quick sense of how much the market is willing to pay for each dollar of profit.
Story Continues
What counts as a “fair” P/E depends on how the market views the company’s growth prospects and its risks. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually points to a lower, more conservative multiple.
AbbVie currently trades at a P/E of 99.73x. That is well above the Biotechs industry average of 17.75x and the peer average of 20.87x. Simply Wall St’s Fair Ratio for AbbVie is 36.70x, which reflects a preferred P/E based on factors such as earnings growth, profit margins, industry, market cap and company specific risks.
This Fair Ratio can be more informative than a simple comparison with peers or the broad industry because it adjusts for AbbVie’s own characteristics rather than assuming it should trade like an average stock. Compared with the current P/E of 99.73x, the Fair Ratio of 36.70x suggests the stock trades above this adjusted benchmark.
Result: OVERVALUEDNYSE:ABBV P/E Ratio as at May 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your AbbVie Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St help you turn your view of AbbVie into a clear story that links its business drivers to a forecast and then to a Fair Value. You can compare this Fair Value with the current price on the Community page used by millions of investors. Each Narrative captures assumptions like the consensus fair value of about US$249 per share and the wide range of analyst price targets from US$184 to US$299. This allows you to see, for example, how a more optimistic view on immunology expansion and margins, or a more cautious view on patent risk and pricing pressure, flows through to different earnings paths, updated automatically as new news or results arrive, and then into a Fair Value that can help you decide whether AbbVie looks attractively or cautiously priced against your own expectations.
Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!NYSE:ABBV 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABBV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
